Business Context and Reporting Period
Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, licensing, and globalizing biopharma innovations, primarily for oncology. The company's lead candidate is firmonertinib, a third-generation tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC). This Form 10-Q covers the quarterly period ended June 30, 2026.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | Balance Sheet (June 30, 2026) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(49,893) | $(93,213) | N/A |
| Operating Expenses | $52,691 | $98,801 | N/A |
| Research & Development | $42,339 | $79,957 | N/A |
| General & Administrative | $10,352 | $18,844 | N/A |
| Interest & Investment Income | $2,798 | $5,588 | N/A |
| Cash & Cash Equivalents | N/A | N/A | $154,682 |
| Short-term Investments | N/A | N/A | $218,437 |
| Total Liquidity | N/A | N/A | $373,119 |
| Accumulated Deficit | N/A | N/A | $(497,854) |
| Debt | N/A | N/A | $0 (Undrawn facility) |
Material Changes vs. Prior Period
- Quarter-over-Quarter (Q2 2026 vs. Q2 2025): Net loss increased by $18.5 million to $49.9 million. Operating expenses rose by $19.1 million, driven by a $14.6 million increase in R&D (primarily due to $9.8 million in early-stage program costs and $5.0 million in Phase 3 trial costs) and a $4.4 million increase in G&A due to headcount growth.
- Year-to-Date (Six Months 2026 vs. Six Months 2025): Net loss decreased slightly by $2.6 million to $93.2 million. Total operating expenses decreased by $1.6 million. This was due to an $18.9 million decrease in early-stage R&D costs (excluding a one-time $40 million upfront payment made in 2025), partially offset by a $7.6 million increase in personnel costs and a $4.7 million increase in Phase 3 trial costs.
- Liquidity: Cash and cash equivalents increased from $45.5 million at year-end 2025 to $154.7 million at June 30, 2026, bolstered by $140.0 million in net proceeds from "at-the-market" stock sales during the period.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring significant operating losses for the foreseeable future as it advances clinical trials. The company believes its current liquidity of $373.1 million is sufficient to fund operations for at least 12 months from the filing date.
- Capital Resources: The company maintains an "at-the-market" (ATM) offering program with approximately $229.1 million remaining capacity as of June 30, 2026. It also has an undrawn $75.0 million term loan facility with Silicon Valley Bank.
- Key Risks:
- Patent Litigation: On July 22, 2026, the USPTO granted a request for ex parte reexamination of U.S. Reissue Patent No. 48,687 covering firmonertinib, alleging obviousness. The outcome could narrow or cancel patent claims.
- Financing: Future profitability depends on raising additional capital; failure to do so could force delays in development.
- Competition: Significant competition exists in the EGFRm NSCLC space, including recently approved therapies and competitors with PDUFA dates approaching.
- Subsequent Event: On August 11, 2026, the company entered into a license agreement with Allist to develop and commercialize ARR-002 in Greater China, potentially generating up to $80.6 million in payments.
Investor Verification Checklist
- Verify the status and potential impact of the USPTO ex parte reexamination on the RE '687 Patent covering firmonertinib.
- Confirm the timeline and enrollment progress of the pivotal Phase 3 trials (FURVENT and ALPACCA) for firmonertinib.
- Monitor the utilization of the remaining $229.1 million ATM facility and the $75.0 million undrawn credit line.
- Review the terms and potential revenue impact of the August 2026 collaboration agreement with Allist regarding ARR-002 in Greater China.
- Assess the burn rate relative to the $373.1 million liquidity position to validate the 12-month runway assertion.